As announced in the recently published Q2 interim report, the Board of Directors of Chr. Hansen regrettably announces that CFO Søren Westh Lonning has decided to pursue his career outside of Chr. Hansen as CFO of a private equity backed, non-competitive company. Søren Westh Lonning has been with Chr. Hansen since 2007, and has been the CFO since 2015. He will leave his position at Chr. Hansen afte
Chr. Hansen reports improved growth momentum in Q2; 5% organic growth in Q2 elevates year-to-date organic growth to 3%
“Verdens mest bæredygtige virksomhed 2019” rangerer som nr. 2 på Corporate Knights’ liste for 2020. Med tre danske virksomheder i top 10 viser Danmark klart lederskab inden for bæredygtighed.
“The world’s most sustainable company 2019” ranks no. 2 on Corporate Knights’ list for 2020.
Organic revenue growth of 1% in the first three months of 2019/20, corresponding to 1% EUR growth, was in line with expectations: Food Cultures & Enzymes 4%, Health & Nutrition (4)% and Natural Colors (1)%. EBIT before special items decreased by 1% to EUR 70 million, corresponding to an EBIT margin b.s.i. of 25.7%, down 0.6%-point compared to last year. The organic growth outlook for 2019/
Chr. Hansen and Lonza’s 50/50 joint venture for Live Biotherapeutic Products (LBP), Bacthera, announces Lukas Schüpbach as the company’s CEO
Up to one in four infants globally suffer from excessive crying and fussing – often called colic. A new study shows that the BB-12® probiotic strain may help reduce crying duration and the number of crying episodes and bring relief to infants and their parents
Global platform brings together the top 100 business leaders who are combining profit and purpose to help achieve the UN Sustainable Development Goals
Despite more challenging growth conditions Chr. Hansen delivers a strong EBIT margin and a healthy cash flow, while also making significant progress on key strategic priorities
A new 10-year agreement enables Chr. Hansen Denmark to switch 100% to green power from two brand new solar parks. The agreement underlines Chr. Hansen’s commitment to a sustainable future and will create more green energy capacity to the benefit of all of Denmark.
En ny tiårig aftale med Better Energy betyder, at Chr. Hansen kan overgå 100% til grøn strøm fra to helt nye solcelleparker. Aftalen understreger Chr. Hansens dedikation til en bæredygtig fremtid og skaber mere grøn energi til hele Danmark.
Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
